nach oben

Journal of Neural Transmission

Erschienen in:

01.08.2008 | Alzheimer's Disease and Related Disorders - Original Article

Decreased phospholipase A₂ activity in cerebrospinal fluid of patients with dementia

verfasst von: Stefan Smesny, Susan Stein, Ingo Willhardt, Jürgen Lasch, Heinrich Sauer

Erschienen in: Journal of Neural Transmission | Ausgabe 8/2008

Einloggen, um Zugang zu erhalten

Abstract

Phospholipase A₂ (PLA₂) is involved in important aspects of dementia, for example neurotransmission and memory processing, membrane function, choline availability, and antioxidative defense. Reduced PLA₂-activity has been reported so far in blood samples and postmortem neuronal tissue in Alzheimer disease. For the first time, we studied PLA₂ in cerebrospinal fluid (CSF) in Alzheimer disease (AD), vascular (VD), and mixed Alzheimer/vascular dementia (MD). Intracellular PLA₂ was assessed in CSF of 16 AD, 12 VD, 15 MD patients, and 19 healthy control subjects. A fluorometric assay was applied using the PLA₂-specific substrate NBDC6-HPC. Significantly reduced PLA₂ activity was not only found in AD, but also in VD and MD. This finding was independent of demographic co-variates and medication. PLA₂ results in CSF corroborate previous findings of impaired PLA₂ function in Alzheimer’s disease and extend these to patients with VD. They are likely to reflect an involvement of PLA₂ impairment in a variety of pathomechanisms crucial in different dementia subtypes, in which disruption of cholinergic neurotransmission and disturbance of intact membrane function appear to be the key mechanisms.

Albers M, Meurer H, Marki F, Klotz J (1993) Phospholipase A₂ activity in serum of neuroleptic-naive psychiatric inpatients. Pharmacopsychiatry 26:94–98PubMed

Baba N, Nikami Y, Shigeta Y, Nakajima S, Kaneko T, Matsuo M (1993) Hydrolysis of glycerophosphocholine hydroperoxide by phospholipase A₂. Biosci Biotechnol Biochem 57:2200–2201

Balsinde J, Balboa MA, Insel PA, Dennis EA (1999) Regulation and inhibition of phospholipase A2. Annu Rev Pharmacol Toxicol 39:175–89PubMedCrossRef

Barbour SE, Kapur A, Deal CL (1999) Regulation of phosphatidylcholine homeostasis by calcium-independent phospholipase A₂. Biochim Biophys Acta 1439:77–88PubMed

Battaglia F, Wang HY, Ghilardi MF, Gashi E, Quartarone A, Friedman E, Nixon RA (2007) Cortical plasticity in Alzheimer’s disease in humans and rodents. Biol Psychiatry 62:1405–1412PubMedCrossRef

Bickel H (2000) Dementia syndrome and Alzheimer disease: an assessment of morbidity and annual incidence in Germany. Health Care 62:211–218

Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, Perl DP, Schmeidler J, Kanof P, Davis KL (1995) Neurochemical correlates of dementia severity in Alzheimer’s disease: relative importance of the cholinergic deficits. J Neurochem 64:749–760PubMed

Bloch-Shilderman E, Abu-Raya S, Trembovler V, Boschwitz H, Gruzman A, Linial M, Lazarovici P (2002) Pardaxin stimulation of phospholipases A₂ and their involvement in exocytosis in PC–12 cells. J Pharmacol Exp Ther 301:953–962PubMedCrossRef

Blusztajn JK, Liscovitch M, Richardson UI (1987) Synthesis of acetylcholine from choline derived from phosphatidylcholine in a human neuronal cell line. Proc Natl Acad Sci USA 84:5474–5477PubMedCrossRef

Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, Younkin L, Good MA, Bliss TV, Hyman BT, Younkin SG, Hsiao KK (1999) Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 2:271–276PubMedCrossRef

Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R (1992) Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer’s Disease Diagnostic and Treatment Centers. Neurology 42:473–480PubMed

Clarke MS, Prendergast MA, Terry AV Jr (1999) Plasma membrane ordering agent pluronic F–68 (PF–68) reduces neurotransmitter uptake and release and produces learning and memory deficits in rats. Learn Mem 6:634–649PubMedCrossRef

Cohen CA, Gold DP, Shulman KI, Wortley JT, McDonald G, Wargon M (1993) Factors determining the decision to institutionalize dementing individuals: a prospective study. Gerontologist 33:714–720PubMed

Dawson GR, Seabrook GR, Zheng H, Smith DW, Graham S, O’Dowd G, Bowery BJ, Boyce S, Trumbauer ME, Chen HY, Van der Ploeg LH, Sirinathsinghji DJ (1999) Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience 90:1–13PubMedCrossRef

Dennis EA (1994) Diversity of group types, regulation, and function of phospholipase A2. J Biol Chem 269:13057–13060PubMed

Eckert GP, Cairns NJ, Maras A, Gattaz WF, Muller WE (2000) Cholesterol modulates the membrane-disordering effects of beta-amyloid peptides in the hippocampus: specific changes in Alzheimer’s disease. Dement Geriatr Cogn Disord 11:181–186PubMedCrossRef

Farooqui AA, Hirashima Y, Horrocks LA (1992) Brain phospholipases and their role in signal transduction. In: Bazan NG, Toffano G, Murphy M (eds) Neurobiology of essential fatty acids. Plenum Press, New York, pp 11–25

Farooqui AA, Horrocks LA, Farooqui T (2000) Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. Chem Phys Lipids 106:1–29PubMedCrossRef

Farooqui AA, Ong WY, Horrocks LA (2004) Biochemical aspects of neurodegeneration in human brain: involvement of neural membrane phospholipids and phospholipases A₂. Neurochem Res 29:1961–1977PubMedCrossRef

Folstein MF, Folstein SE, Hugh PR (1975) “Mini-Mental State”. A practical method for grading the cognitive state of patients for the clinican. J Psychiatr Res 12:189–198PubMedCrossRef

Fujita S, Ikegaya Y, Nishikawa M, Nishiyama N, Matsuki N (2001) Docosahexaenoic acid improves long-term potentiation attenuated by phospholipase A₂ inhibitor in rat hippocampal slices. Br J Pharmacol 132:1417–1422PubMedCrossRef

Fujita S, Ikegaya Y, Nishiyama N, Matsuki N (2000) Ca²⁺-independent phospholipase A₂ inhibitor impairs spatial memory of mice. Jpn J Pharmacol 83:277–278PubMedCrossRef

Gattaz WF, Kollisch M, Thuren T, Virtanen JA, Kinnunen PK (1987) Increased plasma phospholipase-A₂ activity in schizophrenic patients: reduction after neuroleptic therapy. Biol Psychiatry 22:421–426PubMedCrossRef

Gattaz WF, Hubner CV, Nevalainen TJ, Thuren T, Kinnunen PK (1990) Increased serum phospholipase A₂ activity in schizophrenia: a replication study. Biol Psychiatry 28:495–501PubMed

Gattaz WF, Schmitt A, Maras A (1995) Increased platelet phospholipase A₂ activity in schizophrenia. Schizophr Res 16:1–6PubMedCrossRef

Gattaz WF, Cairns NJ, Levy R, Forstl H, Braus DF, Maras A (1996a) Decreased phospholipase A₂ activity in the brain and in platelets of patients with Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 246:129–131PubMedCrossRef

Gattaz WF, Levy R, Cairns NJ, Forstl H, Braus DF, Maras A (1996b) Relevance of metabolism of membrane phospholipids for Alzheimer dementia. Prog Neurol Psychiatry 64:8–12

Gattaz WF, Forlenza OV, Talib LL, Barbosa NR, Bottino CM (2004) Platelet phospholipase A₂ activity in Alzheimer’s disease and mild cognitive impairment. J Neural Transm 111:591–601PubMedCrossRef

Gsell W, Strein I, Riederer P (1996) The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared. J Neural Transm 47:73–101

Gsell W, Jungkunz G, Riederer P (2004) Functional neurochemistry of Alzheimer’s disease. Curr Pharm Des 10:265–293PubMedCrossRef

Hentschel F, Supprian T, Frölich L (2005) Alzheimer’s dementia versus vaskular dementia—dichotomia or interaction? Prog Neurol Psychiatry 73:317–326

Hölscher C, Rose SP (1994) Inhibitors of phospholipase A₂ produce amnesia for a passive avoidance task in the chick. Behav Neural Biol 61:225–232PubMedCrossRef

Hölscher C, Canevari L, Richter-Levin G (1995) Inhibitors of PLA₂ and NO synthase cooperate in producing amnesia of a spatial task. Neuroreport 6:730–2PubMed

Hong A (1995) The neural basis of learning and memory declines in aged rats. Sheng Li Ke Xue Jin Zhan 26:240–242PubMed

Ihara Y, Hayabara T, Sasaki K, Fujisawa Y, Kawada R, Yamamoto T, Nakashima Y, Yoshimune S, Kawai M, Kibata M, Kuroda S (1997) Free radicals and superoxide dismutase in blood of patients with Alzheimer’s disease and vascular dementia. J Neurol Sci 9:76–81CrossRef

Jellinger KA (2002) Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 109:813–836PubMedCrossRef

Jenkins CM, Han X, Mancuso DJ, Gross RW (2002) Identification of calcium-independent phospholipase A2 (iPLA2) beta, and not iPLA2gamma, as the mediator of arginine vasopressin-induced arachidonic acid release in A–10 smooth muscle cells. Enantioselective mechanism-based discrimination of mammalian iPLA2 s. J Biol Chem 277:32807–14PubMedCrossRef

Kalaria RN, Ballard C (1999) Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 13:115–123CrossRef

Katila H, Appelberg B, Rimon R (1997) No differences in phospholipase-A₂ activity between acute psychiatric patients and controls. Schizophr Res 26:103–105PubMedCrossRef

Lasch J, Willhardt I, Kinder D, Sauer H, Smesny S (2003) Fluorometric assays of phospholipase A₂ activity with three different substrates in biological samples of patients with schizophrenia. Clin Chem Lab Med 41:908–914PubMedCrossRef

Law MH, Cotton RG, Berger GE (2006) The role of phospholipases A₂ in schizophrenia. Mol Psychiatry 11:547–556PubMedCrossRef

Lucas KK, Svensson CI, Hua XY, Yaksh TL, Dennis EA (2005) Spinal phospholipase A2 in inflammatory hyperalgesia: role of group IVA cPLA2. Br J Pharmacol 144:940–952PubMedCrossRef

Mattson MP (2002) Oxidative stress, perturbed calcium homeostasis, and immune dysfunction in Alzheimer’s disease. J Neurovirol 8:539–550PubMedCrossRef

McLean LR, Hagaman KA, Davidson WS (1993) Role of lipid structure in the activation of phospholipase A₂ by peroxidized phospholipids. Lipids 28:505–509PubMedCrossRef

Mecocci R, Cherubini A, Beal MF, Cecchetti R, Chionne E, Polidori MC, Romano G, Senin U (1996) Altered mitochondrial membrane fluidity in AD brain. Neurosci Lett 207:129–132PubMedCrossRef

Mecocci P, Beal MF, Cecchetti R, Polidori MC, Cherubini A, Chionne F, Avellini L, Romano G, Senin U (1997) Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. Mol Chem Neuropathol 31:53–64PubMedCrossRef

Morris JC (1997) Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 9:173–176PubMedCrossRef

Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C (1989) The consortium to establish a registry for alzheimer’s disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology 39:1159–1165PubMed

Morton RA, Kuenzi FM, Fitzjohn SM, Rosahl TW, Smith D, Zheng H, Shearman M, Collingridge GL, Seabrook GR (2002) Impairment in hippocampal long-term potentiation in mice under-expressing the Alzheimer’s disease related gene presenilin-1. Neurosci Lett 319:37–40PubMedCrossRef

Noponen M, Sanfilipo M, Samanich K, Ryer H, Ko G, Angrist B, Wolkin A, Duncan E, Rotrosen J (1993) Elevated PLA₂ activity in schizophrenics and other psychiatric patients. Biol Psychiatry 34:641–649PubMedCrossRef

Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60:759–767PubMed

Oswald WD, Fleischmann UM (1999) Nürnberger-Alters-Inventar (NAI). Testmanual und Textband, Hogrefe, Göttingen

Paragh G, Balla P, Katona E, Seres I, Egerhazi A, Degrell I (2002) Serum paraoxonase activity changes in patients with Alzheimer’s disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 252:63–67PubMedCrossRef

Perry G, Cash AD, Smith MA (2002) Alzheimer's disease and oxidative stress. J Biomed Biotechnol 2:120–123PubMedCrossRef

Pratt RD, Perdomo CA (2002) Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits. Ann NY Acad Sci 977:513–522PubMedCrossRef

Ray P, Ishida H, Millard CB, Petrali JP, Ray R (1999) Phospholipaise A₂ and arachidonic acid-mediated mechanism of neuroexocytosis: a possible target of botidinum neurotoxin A other then SNAP-25. J Appl Toxicol 19:27–28CrossRef

Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A (1993) Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43:250–260PubMed

Ross BM, Hudson C, Erlich J, Warsh JJ, Kish SJ (1997) Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A₂. Arch Gen Psychiatry 54:487–494PubMed

Ross BM, Moszczynska A, Erlich J, Kish SJ (1998) Phospholipid-metabolizing enzymes in Alzheimer’s disease: increased lysophospholipid acyltransferase activity and decreased phospholipase A₂ activity. J Neurochem 70:786–793PubMed

Ross BM, Turenne S, Moszczynska A, Warsh JJ, Kish SJ (1999) Differential alteration of phospholipase A₂ activities in brain of patients with schizophrenia. Brain Res 821:407–413PubMedCrossRef

Salgo MG, Corongiu FP, Sevanian A (1993) Enhanced interfacial catalysis and hydrolytic specificity of phospholipase A₂ toward peroxidized phosphatidylcholine vesicles. Arch Biochem Biophys 304:123–132PubMedCrossRef

Sato T, Ishida T, Irifune M, Tanaka K, Hirate K, Nakamura N, Nishikawa T (2007) Effect of NC-1900, an active fragment analog of arginine vasopressin, and inhibitors of arachidonic acid metabolism on performance of a passive avoidance task in mice. Eur J Pharmacol 560:36–41PubMedCrossRef

Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer’s disease. J Neurochem 68:2092–2097PubMedCrossRef

Schaeffer EL, Gattaz WF (2005) Inhibition of calcium-independent phospholipase A2 activity in rat hippocampus impairs acquisition of short- and long-term memory. Psychopharmacology 181:392–400PubMedCrossRef

Schaeffer EL, Gattaz WF (2007) Requirement of hippocampal phospholipase A2 activity for long-term memory retrieval in rats. J Neural Transm 114:379–385PubMedCrossRef

Schaeffer EL, Bassi F Jr, Gattaz WF (2005) Inhibition of phospholipase A₂ activity reduces membrane fluidity in rat hippocampus. J Neural Transm 112:641–647PubMedCrossRef

Seigerschmidt E, Mösch E, Siemen M, Förstl H, Bickel H (2002) The clock drawing test and questionable dementia: Reliability and validity. Int J Geriatr Psychiatr 17:1048–1054CrossRef

Shulman KI (2000) Clock-drawing: is it the ideal cognitive screening test? Int J Geriatr Psychiatry 15:548–561PubMedCrossRef

Six DA, Dennis EA (2000) The expanding superfamily of phospholipase A₂ enzymes: classification and characterization. Biochim Biophys Acta 1488:1–19PubMed

Smesny S, Kinder D, Willhardt I, Rosburg T, Lasch J, Berger G, Sauer H (2005) Increased Calcium-independent phospholipase A₂ activity in first but not in multi-episode chronic schizophrenia. Biol Psychiatry 57:399–405PubMedCrossRef

Song H, Ramanadham S, Bao S, Hsu FF, Turk J (2006) A bromoenol lactone suicide substrate inactivates group VIA phospholipase A2 by generating a diffusible bromomethyl keto acid that alkylates cysteine thiols. Biochemistry 45:1061–73PubMedCrossRef

Sun GY, Xu J, Jensen MD, Simonyi A (2004) Phospholipase A₂ in the central nervous system: implications for neurodegenerative diseases. Lipid Res 45:205–213CrossRef

Talbot K, Young RA, Jolly-Tornetta C, Lee VM, Trojanowski JQ, Wolf BA (2000) A frontal variant of Alzheimer’s disease exhibits decreased calcium-independent phospholipase A₂ activity in the prefrontal cortex. Neurochem Int 37:17–31PubMedCrossRef

Taketo MM, Masahiro S (2002) Phospholipase A2 and apoptosis. Biochim Biophys Acta 1585:72–76PubMed

Tavares H, Yacubian J, Talib LL, Barbosa NR, Gattaz WF (2003) Increased phospholipase A₂ activity in schizophrenia with absent response to niacin. Schizophr Res 61:1–6PubMedCrossRef

Tomimoto H, Ohtani R, Shibata M, Nakamura N, Ihara M (2005) Loss of cholinergic pathways in vascular dementia of the Binswanger type. Dement Geriatr Cogn Disord 19:282–288PubMedCrossRef

van den Berg JJ, Op den Kamp JA, Lubin BH, Kuypers FA (1993) Conformational changes in oxidized phospholipids and their preferential hydrolysis by phospholipase A₂: a monolayer study. Biochemistry 32:4962–4967PubMedCrossRef

White MC, McHowat J (2007) Protease activation of calcium-independent phospholipase A2 leads to neutrophil recruitment to coronary artery endothelial cells. Thromb Res 120:597–605PubMedCrossRef

Wolf MJ, Izumi Y, Zorumski CF, Gross RW (1995) Long-term potentiation requires activation of calcium-independent phospholipase A₂. FEBS Lett 377:358–362PubMedCrossRef

Titel: Decreased phospholipase A2 activity in cerebrospinal fluid of patients with dementia
verfasst von: Stefan Smesny
Susan Stein
Ingo Willhardt
Jürgen Lasch
Heinrich Sauer
Publikationsdatum: 01.08.2008
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 8/2008
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-008-0081-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

18.04.2024 | Arterielle Hypertonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Decreased phospholipase A₂ activity in cerebrospinal fluid of patients with dementia

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2008

Selective loss of P2Y2 nucleotide receptor immunoreactivity is associated with Alzheimer’s disease neuropathology

Dopaminergic modulation of emotional memory in Parkinson’s disease

Deficiency of brain 5-HT synthesis but serotonergic neuron formation in Tph2 knockout mice

Effect of locus coeruleus denervation on levodopa-induced motor fluctuations in hemiparkinsonian rats

Auditory processing of sine tones before, during and after ECT in depressed patients by fMRI

Cortical control of gait in healthy humans: an fMRI study

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie